# Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

> **NCT04824131** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 55 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Oral cabotegravir (CAB)
- **DRUG:** CAB LA
- **DRUG:** Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

## Key facts

- **NCT ID:** NCT04824131
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824131, "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04824131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*